Abcam plc

19.95+0.0500+0.25%Vol 2.86K1Y Perf 0.71%
Apr 16th, 2021 10:17 DELAYED
BID19.92 ASK19.98
Open19.89 Previous Close19.90
Pre-Market- After-Market-
 - -%  - -
Target Price
22.33 
Analyst Rating
— — 0.00
Potential %
12.10 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     63.14
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     57.00
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     87.71
Market Cap4.52B 
Earnings Rating
Price Range Ratio 52W %
32.09 
Earnings Date
-

Today's Price Range

19.8619.96

52W Range

17.7124.69

5 Year PE Ratio Range

26.4071.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
0.05%
1 Month
-7.01%
3 Months
-13.48%
6 Months
-
1 Year
0.71%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ABCM19.950.05000.25
AAPL134.48-0.0200-0.01
GOOG2 291.84-4.8200-0.21
MSFT260.300.80000.31
XOM56.53-0.4500-0.79
WFC42.940.70001.66
JNJ161.030.64000.40
FB306.58-1.2400-0.40
GE13.46-0.0900-0.66
JPM153.621.45000.95
Financial StrengthValueIndustryS&P 500US Markets
3.80
5.60
0.15
0.19
-0.70
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
70.00
-0.60
11.60
17.40
-1.36
RevenueValueIndustryS&P 500US Markets
331.72M
1.46
4.77
11.70
DividendsValueIndustryS&P 500US Markets
-
-
42.03
-4.86
Payout ratio202.00
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume2.86K
Shares Outstanding226.72M
Trades Count55
Dollar Volume710.47K
Avg. Volume175.23K
Avg. Weekly Volume103.68K
Avg. Monthly Volume177.97K
Avg. Quarterly Volume152.31K

Abcam plc (NASDAQ: ABCM) stock closed at 19.9 per share at the end of the most recent trading day (a 1.74% change compared to the prior day closing price) with a volume of 82.20K shares and market capitalization of 4.52B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1500 people. Abcam plc CEO is Alan Thomas Hirzel.

The one-year performance of Abcam plc stock is 0.71%, while year-to-date (YTD) performance is -7.66%. ABCM stock has a five-year performance of %. Its 52-week range is between 17.71 and 24.69, which gives ABCM stock a 52-week price range ratio of 32.09%

Abcam plc currently has a PE ratio of -971.70, a price-to-book (PB) ratio of 5.13, a price-to-sale (PS) ratio of 13.28, a price to cashflow ratio of 53.90, a PEG ratio of 2.32, a ROA of -0.26%, a ROC of -0.06% and a ROE of -0.37%. The company’s profit margin is -1.36%, its EBITDA margin is 11.60%, and its revenue ttm is $331.72 Million , which makes it $1.46 revenue per share.

Of the last four earnings reports from Abcam plc, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Abcam plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Abcam plc is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Abcam plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abcam plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of 202.00%.

Abcam plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.23, ATR14 : 0.90, CCI20 : 9.87, Chaikin Money Flow : -0.09, MACD : -0.82, Money Flow Index : 59.49, ROC : 1.38, RSI : 41.99, STOCH (14,3) : 80.20, STOCH RSI : 1.00, UO : 52.53, Williams %R : -19.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abcam plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Abcam plc

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.

CEO: Alan Thomas Hirzel

Telephone: +44 1223696000

Address: Discovery Drive, Cambridge CB2 0AX, , GB

Number of employees: 1 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

75%25%

Bearish Bullish

86%14%

Bearish Bullish

63%38%

News

Stocktwits